Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of chronic nephropathy recently reclassified into immunoglobulin-associated MPGN (Ig-MPGN) and C3 glomerulopathy (C3G). In this study we aimed: (1) to evaluate the complement genetic and biochemical profile in patients with Ig-MPGN/C3G; (2) to investigate whether genetic variants and different patterns of complement activation (i.e., fluid versus solid phase) correlate with disease manifestations and outcomes.

          Related collections

          Author and article information

          Journal
          Mol. Immunol.
          Molecular immunology
          Elsevier BV
          1872-9142
          0161-5890
          Mar 2016
          : 71
          Affiliations
          [1 ] IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Bergamo, Italy.
          [2 ] Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
          [3 ] Unit of Pediatric Nephrology, Dialysis and Transplantation, Azienda Ospedaliera of Padova, Italy.
          [4 ] Department of Immunology, Assistance Publique-Hopitaux de Paris, Hopital Europeen George-Pompidou and INSERM UMRS 1138, Cordelier Research Center, Complement and Diseases Team, Paris, France.
          [5 ] Division of Nephrology and Dialysis, Bambin Gesù Pediatric Hospital, Roma, Italy.
          [6 ] IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Bergamo, Italy. Electronic address: erica.daina@marionegri.it.
          [7 ] IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
          Article
          S0161-5890(16)30011-6
          10.1016/j.molimm.2016.01.010
          26895476

          Comments

          Comment on this article